EdgarLookup

Lemonade, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Lemonade, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-22.4%
Profit Margin
Net income ÷ revenue
-8.6%
Return on Assets
Net income ÷ assets
2.61x
Debt-to-Equity
Total liabilities ÷ equity
+40.2%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $737.90M Feb 25, 2026
FY2025 Dec 31, 2024 $526.50M Feb 25, 2026
FY2025 Dec 31, 2023 $429.80M Feb 25, 2026
FY2024 Dec 31, 2022 $256.70M Feb 26, 2025
FY2023 Dec 31, 2021 $128.40M Feb 28, 2024
FY2022 Dec 31, 2020 $94.40M Mar 3, 2023
FY2021 Dec 31, 2019 $67.30M Mar 1, 2022
FY2020 Dec 31, 2018 $22.50M Mar 8, 2021

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($165.50M) Feb 25, 2026
FY2025 Dec 31, 2024 ($202.20M) Feb 25, 2026
FY2025 Dec 31, 2023 ($236.90M) Feb 25, 2026
FY2024 Dec 31, 2022 ($297.80M) Feb 26, 2025
FY2023 Dec 31, 2021 ($241.30M) Feb 28, 2024
FY2022 Dec 31, 2020 ($122.30M) Mar 3, 2023
FY2021 Dec 31, 2019 ($108.50M) Mar 1, 2022
FY2020 Dec 31, 2018 ($52.90M) Mar 8, 2021

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $93.90M Feb 25, 2026
FY2025 Dec 31, 2024 $85.80M Feb 25, 2026
FY2025 Dec 31, 2023 $88.80M Feb 25, 2026
FY2024 Dec 31, 2022 $79.60M Feb 26, 2025
FY2023 Dec 31, 2021 $51.80M Feb 28, 2024
FY2022 Dec 31, 2020 $19.40M Mar 3, 2023
FY2021 Dec 31, 2019 $9.80M Mar 1, 2022
FY2020 Dec 31, 2018 $4.70M Mar 8, 2021

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($16.50M) Feb 25, 2026
FY2025 Dec 31, 2024 ($11.40M) Feb 25, 2026
FY2025 Dec 31, 2023 ($119.10M) Feb 25, 2026
FY2024 Dec 31, 2022 ($163.00M) Feb 26, 2025
FY2023 Dec 31, 2021 ($144.60M) Feb 28, 2024
FY2022 Dec 31, 2020 ($91.70M) Mar 3, 2023
FY2021 Dec 31, 2019 ($78.10M) Mar 1, 2022
FY2020 Dec 31, 2018 ($40.80M) Mar 8, 2021

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $9.40M Feb 25, 2026
FY2025 Dec 31, 2024 $9.40M Feb 25, 2026
FY2025 Dec 31, 2023 $9.20M Feb 25, 2026
FY2024 Dec 31, 2022 $10.10M Feb 26, 2025
FY2023 Dec 31, 2021 $9.40M Feb 28, 2024
FY2022 Dec 31, 2020 $4.40M Mar 3, 2023
FY2021 Dec 31, 2019 $2.70M Mar 1, 2022
FY2020 Dec 31, 2018 $700.0K Mar 8, 2021

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.93B Feb 25, 2026
FY2025 Dec 31, 2024 $1.85B Feb 25, 2026
FY2024 Dec 31, 2023 $1.63B Feb 26, 2025
FY2023 Dec 31, 2022 $1.69B Feb 28, 2024
FY2022 Dec 31, 2021 $1.51B Mar 3, 2023
FY2021 Dec 31, 2020 $828.70M Mar 1, 2022
FY2020 Dec 31, 2019 $414.30M Mar 8, 2021

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $1.39B Feb 25, 2026
FY2025 Dec 31, 2024 $1.26B Feb 25, 2026
FY2024 Dec 31, 2023 $924.40M Feb 26, 2025
FY2023 Dec 31, 2022 $823.90M Feb 28, 2024
FY2022 Dec 31, 2021 $522.30M Mar 3, 2023
FY2021 Dec 31, 2020 $287.70M Mar 1, 2022
FY2020 Dec 31, 2019 $116.60M Mar 8, 2021

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $533.60M Feb 25, 2026
FY2025 Dec 31, 2024 $593.40M Feb 25, 2026
FY2025 Dec 31, 2023 $708.90M Feb 25, 2026
FY2025 Dec 31, 2022 $866.80M Feb 25, 2026
FY2024 Dec 31, 2021 $988.20M Feb 26, 2025
FY2023 Dec 31, 2020 $541.00M Feb 28, 2024
FY2022 Dec 31, 2019 ($182.50M) Mar 3, 2023
FY2021 Dec 31, 2018 ($79.10M) Mar 1, 2022
FY2020 Dec 31, 2017 ($28.40M) Mar 8, 2021

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $19.00M Feb 25, 2026
FY2025 Dec 31, 2024 $19.00M Feb 25, 2026
FY2024 Dec 31, 2023 $19.00M Feb 26, 2025
FY2023 Dec 31, 2022 $19.00M Feb 28, 2024
FY2022 Dec 31, 2021 $0 Mar 3, 2023

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 ($1.46B) Feb 25, 2026
FY2025 Dec 31, 2024 ($1.30B) Feb 25, 2026
FY2024 Dec 31, 2023 ($1.10B) Feb 26, 2025
FY2023 Dec 31, 2022 ($859.70M) Feb 28, 2024
FY2022 Dec 31, 2021 ($561.90M) Mar 3, 2023
FY2021 Dec 31, 2020 ($320.60M) Mar 1, 2022
FY2020 Dec 31, 2019 ($198.30M) Mar 8, 2021

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 $385.00M Feb 25, 2026
FY2025 Dec 31, 2024 $376.00M Feb 25, 2026
FY2024 Dec 31, 2023 $264.50M Feb 26, 2025
FY2023 Dec 31, 2022 $282.50M Feb 28, 2024
FY2022 Dec 31, 2021 $270.60M Mar 3, 2023
FY2021 Dec 31, 2020 $570.80M Mar 1, 2022
FY2020 Dec 31, 2019 $270.00M Mar 8, 2021

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (2) Feb 25, 2026
FY2025 Dec 31, 2024 (2) Feb 25, 2026
FY2025 Dec 31, 2023 (3) Feb 25, 2026
FY2024 Dec 31, 2022 (4) Feb 26, 2025
FY2023 Dec 31, 2021 (3) Feb 28, 2024
FY2022 Dec 31, 2020 (3) Mar 3, 2023
FY2021 Dec 31, 2019 (9) Mar 1, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 (2) Feb 25, 2026
FY2025 Dec 31, 2024 (2) Feb 25, 2026
FY2025 Dec 31, 2023 (3) Feb 25, 2026
FY2024 Dec 31, 2022 (4) Feb 26, 2025
FY2023 Dec 31, 2021 (3) Feb 28, 2024
FY2022 Dec 31, 2020 (3) Mar 3, 2023
FY2021 Dec 31, 2019 (9) Mar 1, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 31, 2025 75.91M Feb 25, 2026
FY2025 Dec 31, 2024 72.72M Feb 25, 2026
FY2024 Dec 31, 2023 70.16M Feb 26, 2025
FY2023 Dec 31, 2022 69.28M Feb 28, 2024
FY2022 Dec 31, 2021 61.66M Mar 3, 2023
FY2021 Dec 31, 2020 56.77M Mar 1, 2022
FY2020 Dec 31, 2019 11.27M Mar 8, 2021